Our approach
Purpose-built capital at the stage traditional capital skips, in sectors and U.S. regions existing capital overlooks.
Early equity for validated science-based companies at first revenue, to fund the work required to prepare for commercial launch and customer delivery.
We look at the whole company — the team, the technology, real customer traction, the path to profitability, and the benefit its success brings.
Working capital tied to purchase orders, funding the fulfillment of real customer demand without giving up ownership — and repaid as the revenue lands.
We finance first purchase orders, taking on commercialization risk that most traditional lenders won't.
Our SAFE provides flexible capital for commercialization milestones, while follow-on Working Capital loans help capture revenue without additional dilution
Bridge to Commercialization
Financing that moves with the revenue a company is already earning.
Terms and support built around the operator's reality, not the fund's convenience.
Relationships that shorten the distance between a company and its market.
Beyond capital
Manufacturing, sales, supply chain, and partner development.
Published structures, terms, and returns — templatable like the SAFE — for other capital providers to use.
Workshops on cash flow, contracts, and revenue acceleration.
Foundations, government, and industry, working the same problem together.
What we look for
We are not looking for ideas. We are looking for companies that have already done the hard part and are held back by the wrong kind of capital.
Validated technology
The science is settled and the technology works outside the lab, demonstrated in real operating conditions.
Customers already buying
Purchase orders, contracts, or paid pilots. Demand that exists rather than demand that has to be created.
Deep technical differentiation
An advantage built over years of real science, not a feature a competitor can copy in a quarter.
A path to profitability
Economics that can stand on their own, on a timeline set by the company's market rather than by a fund's clock.
Benefit that scales with the company
Technology whose widest adoption is a deeply positive, empowering force for people and the planet.
A gap we can close
The binding constraint is capital to fulfil demand or reach the next stage of production, not more research funding.
The technology is proven, the customer is real. What sits between them should be purpose-built capital.